Entering text into the input field will update the search result below

Natera, Inc. (NTRA) CEO Steve Chapman on Q4 2020 Results - Earnings Call Transcript

Feb. 28, 2021 5:15 AM ETNatera, Inc. (NTRA)
SA Transcripts profile picture
SA Transcripts

Natera, Inc. (NASDAQ:NTRA) Q4 2020 Earnings Conference Call February 25, 2021 4:30 PM ET

Company Participants

Michael Brophy - Chief Financial Officer

Steve Chapman - Chief Executive Officer

Matt Rabinowitz - Co-Founder & Chairman

Solomon Moshkevich - General Manager of Oncology

Conference Call Participants

Tejas Savant - Morgan Stanley

Tycho Peterson - JPMorgan

Doug Schenkel - Cowen

Catherine Schulte - Baird


Welcome to Natera's 2020 Fourth Quarter and Full Year 2020 Financial Results Conference Call. At this time, all participants are in a listen-only mode. Following management’s prepared remarks, we will hold a Q&A session. [Operator Instructions] As a reminder, this conference call is being recorded today, February 25, 2021.

I would now like to turn the conference call over to Michael Brophy, Chief Financial Officer. Please, go ahead.

Michael Brophy

Thanks, operator. Good afternoon. Thank you for joining our conference call to discuss the results of our fourth quarter and full year results for 2020. On the line is Steve Chapman, our CEO; Bob Schueren, Chief Operating Officer; Solomon Moshkevich, General Manager of Oncology; and Paul Billings Chief Medical Officer. Today we also have our Co-Founder and Chairman, Matt Rabinowitz, on to review the results of the SMART trial.

Today's conference call is being broadcast live via webcast. We will be referring to a slide presentation that has been posted to investor.natera.com. A replay of the call will also be available@investor.natera.com.

During the course of this conference call, we will make forward-looking statements, regarding future events and our anticipated future performance, such as our operational and financial outlook, our assumptions for that outlook, the impact of the COVID-19 pandemic on our business and operations, market sizes, partnerships, clinical studies, opportunities and strategies and expectations for various current and future products, including product capabilities, expected release dates, reimbursement coverage and related effects on our financial and operating results.

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.